ABVC Financial Statements From 2010 to 2026

ABVC Stock  USD 1.90  0.01  0.53%   
ABVC Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing ABVC Biopharma's valuation are provided below:
Gross Profit
797.9 K
Market Capitalization
46.2 M
Enterprise Value Revenue
59.1957
Revenue
797.9 K
Earnings Share
(0.28)
We have found one hundred twenty available fundamental signals for ABVC Biopharma, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to validate all of ABVC Biopharma's prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable for few more years. As of February 5, 2026, Market Cap is expected to decline to about 5.9 M. In addition to that, Enterprise Value is expected to decline to about 7.9 M

ABVC Biopharma Total Revenue

615,329

Check ABVC Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ABVC Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 997.3 K, Selling General Administrative of 4.9 M or Total Revenue of 615.3 K, as well as many indicators such as Price To Sales Ratio of 14.77, Dividend Yield of 0.0 or PTB Ratio of 4.8. ABVC financial statements analysis is a perfect complement when working with ABVC Biopharma Valuation or Volatility modules.
  
Build AI portfolio with ABVC Stock
Check out the analysis of ABVC Biopharma Correlation against competitors.
For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.

ABVC Biopharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets9.1 M8.7 M5.1 M
Slightly volatile
Short and Long Term Debt TotalM3.7 MM
Slightly volatile
Total Current Liabilities7.9 M7.5 MM
Slightly volatile
Common Stock Shares Outstanding14.1 M13.4 M3.5 M
Slightly volatile
Liabilities And Stockholders Equity9.1 M8.7 M5.1 M
Slightly volatile
Non Current Liabilities Total282.4 K297.3 K466.6 K
Slightly volatile
Other Stockholder Equity84.1 M80.1 M30.3 M
Slightly volatile
Total Liabilities8.2 M7.8 M4.4 M
Slightly volatile
Total Current Assets1.3 M2.5 M1.6 M
Slightly volatile
Other Current LiabilitiesMM2.2 M
Slightly volatile
Current Deferred Revenue97.9 K93.3 K29.6 K
Slightly volatile
Cash953.3 K993.4 K964.5 K
Slightly volatile
Cash And Short Term Investments972.3 K1.1 M989.3 K
Slightly volatile
Common Stock15.2 K15.9 K46.9 K
Pretty Stable
Net Receivables791.7 K1.3 M890.6 K
Slightly volatile
Property Plant And Equipment Net862.4 K1.3 M834.9 K
Slightly volatile
Non Current Assets Total3.7 M6.2 M3.6 M
Slightly volatile
Property Plant And Equipment Gross5.4 M5.2 M2.2 M
Slightly volatile
Capital Stock11.9 K12.5 K122.2 K
Slightly volatile
Capital Lease Obligations852.7 K576.3 K746 K
Slightly volatile
Non Current Liabilities Other15.4 K24.9 K8.8 K
Slightly volatile

ABVC Biopharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative4.9 M5.8 M4.3 M
Slightly volatile
Total Revenue615.3 K586 K260.2 K
Slightly volatile
Other Operating Expenses4.7 MM4.9 M
Slightly volatile
Cost Of Revenue65268753.6 K
Slightly volatile
Total Operating Expenses4.6 MM4.9 M
Slightly volatile
Depreciation And Amortization219.5 K231.1 K837.9 K
Very volatile
Selling And Marketing Expenses24.4 K25.7 K1.9 M
Slightly volatile
Research Development153.3 K161.3 K4.8 M
Slightly volatile
Interest Income73.2 K100.5 K45.6 K
Slightly volatile
Reconciled Depreciation242.6 K231.1 K72.8 K
Slightly volatile

ABVC Biopharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow878 K993.4 KM
Slightly volatile
Stock Based CompensationM3.2 M1.7 M
Slightly volatile
Issuance Of Capital Stock26.5 K27.9 KM
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio14.7715.5421.8 K
Slightly volatile
Days Sales Outstanding442745624
Slightly volatile
Average Payables25.7 K27 K30.3 K
Slightly volatile
Stock Based Compensation To Revenue5.956.2620.1107
Slightly volatile
Capex To Depreciation0.06090.06411.2749
Pretty Stable
EV To Sales19.7820.8221.9 K
Slightly volatile
Payables Turnover0.890.937.8252
Slightly volatile
Sales General And Administrative To Revenue15.038.8910.3711
Slightly volatile
Average Inventory12.3 K11.7 K9.2 K
Slightly volatile
Research And Ddevelopement To Revenue0.380.476.2111
Slightly volatile
Capex To Revenue0.150.161.0418
Slightly volatile
Cash Per Share0.08690.091590.8863
Slightly volatile
Days Payables Outstanding491517246
Slightly volatile
Intangibles To Total Assets0.520.850.8712
Pretty Stable
Current Ratio0.360.380.354
Slightly volatile
Receivables Turnover0.480.513.3797
Slightly volatile
Capex Per Share0.00530.005656.173
Slightly volatile
Average Receivables496.6 K861.6 K968.1 K
Pretty Stable
Revenue Per Share0.04770.05028.0862
Slightly volatile
Interest Debt Per Share0.380.42.4 K
Slightly volatile
Debt To Assets0.460.491.4233
Slightly volatile
Graham Number1.5 K1.7 K1.9 K
Slightly volatile
Days Of Payables Outstanding491517246
Slightly volatile
Ebt Per Ebit0.911.031.1084
Pretty Stable
Net Income Per E B T1.081.051.002
Very volatile
Cash Ratio0.140.150.2221
Slightly volatile
Days Of Sales Outstanding442745624
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.161.0228
Slightly volatile
Fixed Asset Turnover0.470.510.2129
Slightly volatile
Debt Ratio0.460.491.4233
Slightly volatile
Price Sales Ratio14.7715.5421.8 K
Slightly volatile
Asset Turnover0.140.07770.0617
Slightly volatile

ABVC Biopharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap5.9 M6.2 M272 M
Pretty Stable
Enterprise Value7.9 M8.3 M273.8 M
Pretty Stable

ABVC Fundamental Market Drivers

ABVC Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About ABVC Biopharma Financial Statements

ABVC Biopharma stakeholders use historical fundamental indicators, such as ABVC Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although ABVC Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in ABVC Biopharma's assets and liabilities are reflected in the revenues and expenses on ABVC Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ABVC Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue93.3 K97.9 K
Total Revenue586 K615.3 K
Cost Of Revenue 686.70  652.37 
Stock Based Compensation To Revenue 6.26  5.95 
Sales General And Administrative To Revenue 8.89  15.03 
Research And Ddevelopement To Revenue 0.40  0.38 
Capex To Revenue 0.16  0.15 
Revenue Per Share 0.05  0.05 
Ebit Per Revenue(8.31)(8.73)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock:
Check out the analysis of ABVC Biopharma Correlation against competitors.
For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Will Biotechnology sector continue expanding? Could ABVC diversify its offerings? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ABVC Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.28)
Revenue Per Share
0.046
Quarterly Revenue Growth
1.045
Return On Assets
(0.17)
Return On Equity
(0.48)
Understanding ABVC Biopharma requires distinguishing between market price and book value, where the latter reflects ABVC's accounting equity. The concept of intrinsic value - what ABVC Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push ABVC Biopharma's price substantially above or below its fundamental value.
Understanding that ABVC Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ABVC Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, ABVC Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.